Ambalal Sarabhai [AMBALALSA] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Ambalal Sarabhai Enterprises Ltd. wins in 7 metrics, Sun Pharmaceutical Industries Ltd. wins in 12 metrics, with 0 ties. Sun Pharmaceutical Industries Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Ambalal Sarabhai Enterprises Ltd. | Sun Pharmaceutical Industries Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 23.36 | 36.73 | Ambalal Sarabhai Enterprises Ltd. |
| Price-to-Book Ratio | 1.72 | 5.15 | Ambalal Sarabhai Enterprises Ltd. |
| Debt-to-Equity Ratio | 31.59 | 6.68 | Sun Pharmaceutical Industries Ltd. |
| PEG Ratio | 0.62 | 3.59 | Ambalal Sarabhai Enterprises Ltd. |
| EV/EBITDA | 12.52 | 23.61 | Ambalal Sarabhai Enterprises Ltd. |
| Profit Margin (TTM) | 5.16% | 19.21% | Sun Pharmaceutical Industries Ltd. |
| Operating Margin (TTM) | 10.95% | 26.17% | Sun Pharmaceutical Industries Ltd. |
| EBITDA Margin (TTM) | 10.95% | 26.17% | Sun Pharmaceutical Industries Ltd. |
| Return on Equity | 3.52% | 15.08% | Sun Pharmaceutical Industries Ltd. |
| Return on Assets (TTM) | 1.83% | 11.87% | Sun Pharmaceutical Industries Ltd. |
| Free Cash Flow (TTM) | $-203.34M | $119.44B | Sun Pharmaceutical Industries Ltd. |
| Dividend Yield | N/A | 0.97% | N/A |
| 1-Year Return | -5.76% | 7.25% | Sun Pharmaceutical Industries Ltd. |
| Price-to-Sales Ratio (TTM) | 1.20 | 7.05 | Ambalal Sarabhai Enterprises Ltd. |
| Enterprise Value | $2.77B | $3,783.37B | Sun Pharmaceutical Industries Ltd. |
| EV/Revenue Ratio | 1.36 | 6.66 | Ambalal Sarabhai Enterprises Ltd. |
| Gross Profit Margin (TTM) | 41.99% | 80.96% | Sun Pharmaceutical Industries Ltd. |
| Revenue per Share (TTM) | $26 | $237 | Sun Pharmaceutical Industries Ltd. |
| Earnings per Share (Diluted) | $1.36 | $45.46 | Sun Pharmaceutical Industries Ltd. |
| Beta (Stock Volatility) | -0.14 | 0.11 | Ambalal Sarabhai Enterprises Ltd. |
Ambalal Sarabhai Enterprises Ltd. vs Sun Pharmaceutical Industries Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Ambalal Sarabhai Enterprises Ltd. | -3.15% | 14.81% | 14.78% | 47.15% | 31.73% | 28.76% |
| Sun Pharmaceutical Industries Ltd. | -0.08% | -2.77% | -1.84% | 2.13% | -0.53% | 4.00% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Ambalal Sarabhai Enterprises Ltd. | -5.76% | 68.27% | -36.94% | 323.87% | 381.00% | 225.94% |
| Sun Pharmaceutical Industries Ltd. | 7.25% | 79.99% | 166.96% | 144.01% | 669.48% | 2,278.32% |
Performance & Financial Health Analysis: Ambalal Sarabhai Enterprises Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | AMBALALSA | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹2.43B | ₹3.88T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 84,061 | 3,903,142 |
| 90 Day Avg. Volume | 120,526 | 3,253,866 |
| Last Close | ₹36.03 | ₹1,788.50 |
| 52 Week Range | ₹23.12 - ₹38.85 | ₹1,548.00 - ₹1,916.60 |
| % from 52W High | -7.26% | -6.68% |
| All-Time High | ₹77.70 (Jul 08, 2024) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -53.63% | -8.77% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.13% | 0.14% |
| Quarterly Earnings Growth | 0.37% | 0.16% |
| Financial Health | ||
| Profit Margin (TTM) | 0.05% | 0.19% |
| Operating Margin (TTM) | 0.11% | 0.26% |
| Return on Equity (TTM) | 0.04% | 0.15% |
| Debt to Equity (MRQ) | 31.59 | 6.68 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹18.44 | ₹324.46 |
| Cash per Share (MRQ) | ₹1.73 | ₹115.87 |
| Operating Cash Flow (TTM) | ₹-299,709,000 | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹49.31M | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.97% |
| Last 12-Month Dividend | N/A | ₹16.50 |
Valuation & Enterprise Metrics Analysis: Ambalal Sarabhai Enterprises Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | AMBALALSA (Apr 24, 2026) | SUNPHARMA (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 23.36 | 36.73 |
| Forward P/E | N/A | 29.48 |
| PEG Ratio | 0.62 | 3.59 |
| Price to Sales (TTM) | 1.20 | 7.05 |
| Price to Book (MRQ) | 1.72 | 5.15 |
| Market Capitalization | ||
| Market Capitalization | ₹2.43B | ₹3.88T |
| Enterprise Value | ₹2.77B | ₹3.78T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.36 | 6.66 |
| Enterprise to EBITDA | 12.52 | 23.61 |
| Risk & Other Metrics | ||
| Beta | -0.14 | 0.11 |
| Book Value per Share (MRQ) | ₹18.44 | ₹324.46 |
Financial Statements Comparison: Ambalal Sarabhai Enterprises Ltd. vs Sun Pharmaceutical Industries Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | AMBALALSA (2025) | SUNPHARMA (2025) |
|---|---|---|
| Revenue/Sales | 1.95B | 520.41B |
| Cost of Goods Sold | 1.23B | 121.98B |
| COGS % of Revenue | 62.9% | 23.4% |
| Gross Profit | 723.71M | 398.44B |
| Gross Margin | 37.1% | 76.6% |
| Research & Development | 165,000 | N/A |
| Operating Income (EBIT) | 92.36M | 125.81B |
| Operating Margin | 4.7% | 24.2% |
| EBITDA | 205.00M | 167.25B |
| EBITDA Margin | 10.5% | 32.1% |
| Pre-Tax Income | 48.34M | 137.52B |
| Pre-Tax Income % of Revenue | 2.5% | 26.4% |
| Income Tax | -981,000 | 27.72B |
| Income Tax % of Revenue | -0.1% | 5.3% |
| Net Income (Profit) | 49.32M | 109.65B |
| Profit Margin | 2.5% | 21.1% |
Balance Sheet & Liquidity Metrics
| Metric | AMBALALSA (2025) | SUNPHARMA (2025) |
|---|---|---|
| Cash & Equivalents | 48.95M | 102.69B |
| Total Current Assets | 1.18B | 526.24B |
| Total Current Assets % of Revenue | 60.7% | 101.1% |
| Total Current Liabilities | 1.20B | 181.94B |
| Total Current Liabilities % of Revenue | 61.6% | 35.0% |
| Long-Term Debt | 90.15M | 3.58B |
| Long-Term Debt % of Revenue | 4.6% | 0.7% |
| Total Shareholders Equity | 1.40B | 724.86B |
| Retained Earnings | -28.33M | 578.62B |
| Retained Earnings % of Revenue | -1.5% | 111.2% |
| Property, Plant & Equipment | 50.63M | 100.36B |
Cash Flow Statement Comparison
| Metric | AMBALALSA (2025) | SUNPHARMA (2025) |
|---|---|---|
| Operating Cash Flow | -299.71M | 110.84B |
| Operating Cash Flow % of Revenue | -15.3% | 21.3% |
| Capital Expenditures | -25.45M | -20.68B |
| Free Cash Flow | -203.34M | 119.44B |
| FCF Margin | -10.4% | 23.0% |
| Debt Repayment | N/A | -43.44B |
| Common Stock Repurchase | N/A | -29.00B |
Short Interest & Institutional Ownership Analysis
| Metric | AMBALALSA | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 76.63M | 2.40B |
| Float Shares | 46.90M | 1.07B |
| % Held by Insiders | 34.99% | 55.62% |
| % Held by Institutions | 0.00% | 28.69% |
| % Held by Public | 65.01% | 15.69% |
Dividend Analysis & Yield Comparison: Ambalal Sarabhai Enterprises Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | AMBALALSA | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹16.50 |
| Last 12-Month Dividend Yield | N/A | 0.97% |
| 3-Year Avg Annual Dividend | N/A | ₹17.33 |
| 3-Year Avg Dividend Yield | N/A | 0.51% |
| 3-Year Total Dividends | N/A | ₹52.00 |
| Ex-Dividend Date | N/A | Feb 05, 2026 |